BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo's core platform service offerings across target discovery, drug discovery, optimization, and manufacturing. The group, which will conduct regular meetings at Ginkgo and with its partners, includes (in alphabetical order):
Together, this council represents a wide breadth of technical experience and deep business expertise that will contribute to the development of Ginkgo's service offerings in Gene Therapy, Cell Therapy, RNA, Biologics, Process R&D and more. Over the past year, Ginkgo announced new R&D services collaborations with Boehringer Ingelheim, DARPA, Esperovax, Merck, Pfizer, Prokarium, Sensible, Synplogen, WARF, as well as advancements in its work with Novo Nordisk, Persephone Biosciences, and Synlogic. Ginkgo acquires and integrates new technologies to expand its horizontal platform, with past acquisitions serving to develop Ginkgo's capabilities in AAV and circular RNA.
"The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Advanced technologies in high throughput automation, synthetic biology, and more recently AI, have opened up possibilities for the development of novel modalities and exploration of more design space for the discovery and optimization of new targets and candidate therapies. It's an incredibly exciting time for the industry as these technologies come together at scale, and we're thrilled to have this group of luminaries as part of our inaugural cohort of advisors."
"I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks. "These leaders have shaped the modern vaccines and therapeutics landscapes by spearheading the discovery, testing, manufacturing, and deployment of entirely new modalities, and reinventing how researchers and drugmakers work with more familiar areas of medicine. I can't wait to see how their mentorship, insights, and provocations help our growing team reach new heights."
"We live in a global, interconnected society, and therefore, we are all susceptible to the spread of novel infectious diseases. Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member. "Ginkgo's experience in accelerating biological R&D across modalities and their extensive work in biosecurity and epidemiology positions the company to make a meaningful impact. I look forward to supporting the growth of their team and offerings."
"Ginkgo represents a huge opportunity for businesses who want to take new pharmaceuticals to market. By outsourcing risky R&D to a partner with unprecedented scale, companies can optimize their approach to new modalities and targets wherever they are in the pipeline," said John Maraganore, Ginkgo Biopharma Advisory Board member. "Our industry is at a pivotal moment. More and more of biopharma can leverage scale and AI to turn scientific uncertainty into predictable engineering, so I'm thrilled to be able to contribute to the energy and movement I saw firsthand when I spoke onstage with Jen at Ferment."
To learn more about Ginkgo's biopharmaceutical services offerings, visit https://www.ginkgobioworks.com/offerings/biopharmaceutical/.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell programming platform and its new Biopharma Advisory Board. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
GINKGO BIOWORKS MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.62 |
Daily Change: | -0.22 -2.81 |
Daily Volume: | 589,896 |
Market Cap: | US$328.420M |
September 24, 2024 September 18, 2024 September 17, 2024 August 08, 2024 July 16, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB